Investigating real-world treatment sequencing outcomes in advanced pancreatic cancer: A purple translational registry analysis.
Jordan Santucci, Belinda Lee, Shehara Ramyalini Mendis, Benjamin N Thomson, Michael Michael, Julia Shapiro, Rachel Wong, Kate Clarke, Sharon Tracy Pattison, Matthew E Burge, Robert Richard Zielinski, Mehrdad Nikfarjam, Sumitra Ananda, Lara Rachel Lipton, Peter Gibbs
JOURNAL OF CLINICAL ONCOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2021
386 Background: Current standard combination first line palliative chemotherapy regimens in advanced pancreatic ductal adenocarcinoma (PDAC) have not been compared in head-to-head trials. Data on optimum treatment sequencing is also lacking. Methods: To assess whether first line (1L) treatment with gemcitabine/nab-paclitaxel (Gem/Nab-P)(SEQ1) or FOLFIRINOX (SEQ2) in the palliative treatment setting impacts survival outcomes, data for patients receiving palliative intent combination chemotherapy between 2016 and May 2020 was extracted from PURPLE, a prospective pancreatic cancer registry enrolling consecutive patients across multiple institutions. Results: Of 637 patients, 180 (28%) who rece..View full abstract